CCN2 and pulmonary fibrosis: This antibody is generated to neutralize CTGF activity and to create the disease symptoms in mouse models and clinical trials, including those of muscular dystrophy, liver fibrosis, diabetes, and idiopathic pulmonary fibrosis [2,43,84,120].